Modality
mAb
MOA
EZH2i
Target
PD-L1
Pathway
Proteasome
CeliacPSP
Development Pipeline
Preclinical
~Mar 2010
→ ~Jun 2011
Phase 1
~Sep 2011
→ ~Dec 2012
Phase 2
~Mar 2013
→ ~Jun 2014
Phase 3
~Sep 2014
→ ~Dec 2015
NDA/BLA
~Mar 2016
→ ~Jun 2017
Approved
Sep 2017
→ Oct 2030
ApprovedCurrent
NCT06124012
828 pts·PSP
2022-06→2030-10·Completed
NCT06460126
883 pts·Celiac
2017-09→2030-04·Terminated
NCT03767581
2,806 pts·Celiac
2025-08→2030-02·Not yet recruiting
4,517 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2030-02-113.9y awayPh3 Readout· Celiac
2030-04-264.1y awayPh3 Readout· Celiac
2030-10-034.5y awayPh3 Readout· PSP
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Termina…
Approved
Complet…
Approved
Not yet…
Catalysts
Ph3 Readout
2030-02-11 · 3.9y away
Celiac
Ph3 Readout
2030-04-26 · 4.1y away
Celiac
Ph3 Readout
2030-10-03 · 4.5y away
PSP
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06124012 | Approved | PSP | Completed | 828 | PFS |
| NCT06460126 | Approved | Celiac | Terminated | 883 | Biomarker |
| NCT03767581 | Approved | Celiac | Not yet recr... | 2806 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |